Biotech | February 17, 2022
Center for Breakthrough Medicines launches analytical testing
More than 2,500 submissions are currently under review in the Food and Drug Administration's (FDA) cell and gene therapy pipeline
More than 2,500 submissions are currently under review in the Food and Drug Administration's (FDA) cell and gene therapy pipeline
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong
Apexxnar is the first pneumococcal conjugate vaccine to help protect adults ages 18 years and older against 20 serotypes responsible for the majority of invasive disease and pneumococcal pneumonia
It will open new frontier for south-to-south collaboration and innovation transfer
Immune responses were about two-to-three-fold higher in adolescents than in adults against all variants studied. Vaccine was well-tolerated with no safety signals identified
It is being developed by Pune-based Gennova Biopharmaceuticals
EBITDA from Continuing Operations at Rs. 582 crore recorded a growth of 31 %.
Newly formed Life Science Services business unit to offer fully integrated CDMO and Contract Testing Services
Pfizer and Moderna are also working on vaccines that target the Omicron variant
Subscribe To Our Newsletter & Stay Updated
